文献速递甲状腺疾病

Wnt/β-catenin激活与TP53突变与晚期甲状腺癌不同免疫表型相关

Wnt/B-catenin Activation and TP53 Mutations Associate With Distinct Immune Profiles in Advanced Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究探讨晚期甲状腺癌免疫表型差异的机制,发现未分化甲状腺癌(ATC)常见TP53突变(83.3%),与热免疫表型相关;低分化甲状腺癌(PDTC)TP53突变率低(12.5%),常呈冷免疫表型。冷癌和PDTC中β-catenin过表达,提示Wnt/β-catenin通路激活通过下调CCL4驱动免疫排斥。p53功能丧失与β-catenin表达呈负相关,p53突变癌较野生型CCL4表达和CD103+树突状细胞密度显著更高。结论基于观察性数据,需实验研究确定因果关系。

要点

  • ATC中TP53突变率83.3%,与热免疫表型及CCL4高表达、CD103+树突状细胞募集相关。
  • PDTC中TP53突变率12.5%,常呈冷免疫表型,β-catenin过表达提示Wnt通路激活驱动免疫排斥。
  • p53突变癌较p53野生型CCL4表达和CD103+树突状细胞密度显著更高。

核心结论

  • Wnt/β-catenin通路激活与冷甲状腺癌发生可能存在相关性,可能由CCL4表达抑制介导。
  • p53基因突变似乎与热甲状腺癌发生相关。
  • 这些关联基于观察性数据,需实验研究确定因果关系。

研究设计与样本

  • 观察性研究,比较ATC与PDTC的免疫相关基因表达谱、TP53突变状态、β-catenin表达及CCL4与CD103+树突状细胞。

主要发现

  • ATC中TP53突变率为83.3%,与热免疫表型相关,特征为β-catenin调控的细胞因子CCL4高表达和CD103+树突状细胞募集。
  • PDTC中TP53突变率为12.5%,常呈冷免疫表型;冷癌和PDTC中β-catenin过表达,提示Wnt/β-catenin通路激活通过下调CCL4驱动免疫排斥。
  • p53功能丧失与β-catenin表达呈负相关。
  • p53突变癌较p53野生型 counterparts 的CCL4表达和CD103+树突状细胞密度显著更高。
  • p53突变ATC表达更多免疫相关基因,支持p53丧失在激活癌症免疫反应中的作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些关联基于观察性数据。
  • 需要实验研究来确定这些发现的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Anaplastic thyroid carcinomas (ATCs) and poorly differentiated thyroid carcinomas (PDTCs) exhibit distinct immune-related gene expression profiles. Most ATCs are characterized by active immune interactions (hot or altered immunosuppressed immunophenotypes), while PDTCs are largely immunologically inert (cold immunophenotypes). OBJECTIVE: This study aimed to elucidate the mechanisms driving these divergent immunological fates, focusing on the Wnt/β-catenin pathway and TP53 mutations. RESULTS: Our data reveal that ATCs frequently harbor TP53 mutations (83.3%), which correlate with a hot immunophenotype, characterized by high expression of β-catenin-regulated cytokine CCL4 and recruitment of CD103 + dendritic cells. Conversely, PDTCs, with a lower incidence of TP53 mutations (12.5%), often exhibit a cold immunophenotype. In cold cancers and PDTCs, β-catenin is overexpressed, suggesting that Wnt/β-catenin pathway activation drives immune exclusion through CCL4 downregulation.Further analysis indicated that loss of p53 function is inversely correlated with β-catenin expression. P53-mutated cancers showed significantly higher expression of CCL4 and densities of CD103 + dendritic cells compared to their p53-wild-type counterparts. Additionally, p53-mutated ATCs expressed a higher number of immune-related genes, supporting the role of p53 loss in activating immune responses in cancer. CONCLUSION: Our study indicates a potential correlation between the activation of the Wnt/β-catenin pathway and the development of cold thyroid cancers, which may be mediated by the suppression of CCL4 expression. Concurrently, mutations in the p53 gene appear to be linked with the occurrence of hot thyroid cancers. While these associations are compelling, they are based on observational data. Experimental research is necessary to determine the causal relationships underlying these findings.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Moretti S, Mandarano M, Menicali E, et al. Wnt/B-catenin Activation and TP53 Mutations Associate With Distinct Immune Profiles in Advanced Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39328078. doi:10.1210/clinem/dgae667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。